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ABSTRACT
Objective: The Polycomb Repressive Complexes (PRC) 1 and 2 function to epigenetically repress target genes. The PRC1 component, Bmi1,
plays a crucial role in maintenance of glucose homeostasis and beta cell mass through repression of the Ink4a/Arf locus. Here we have explored
the role of Bmi1 in regulating glucose homeostasis in the adult animal, which had not been previously reported due to poor postnatal survival of
Bmi1 /  mice.
Methods: The metabolic phenotype of Bmi1þ/  mice was characterized, both in vivo and ex vivo. Glucose and insulin tolerance tests and
hyperinsulinemic-euglycemic clamps were performed. The insulin signaling pathway was assessed at the protein and transcript level.
Results: Here we report a negative correlation between Bmi1 levels and insulin sensitivity in two models of insulin resistance, aging and liver-
speciﬁc insulin receptor deﬁciency. Further, heterozygous loss of Bmi1 results in increased insulin sensitivity in adult mice, with no impact on
body weight or composition. Hyperinsulinemic-euglycemic clamp reveals increased suppression of hepatic glucose production and increased
glucose disposal rate, indicating elevated glucose uptake to peripheral tissues, in Bmi1þ/  mice. Enhancement of insulin signaling, speciﬁcally
an increase in Akt phosphorylation, in liver and, to a lesser extent, in muscle appears to contribute to this phenotype.
Conclusions: Together, these data deﬁne a new role for Bmi1 in regulating insulin sensitivity via enhancement of Akt phosphorylation.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. INTRODUCTION
Type 2 diabetes is characterized by a relative insulin deﬁciency and is
associated with insulin resistance in the peripheral tissues. Insulin
resistance has been shown to be associated with aging, thus exac-
erbating the risk for disease development with age [1].A tﬁrst,
pancreatic beta cells are able to compensate by releasing more insulin.
As insulin resistance progresses, the beta cells fail, resulting in overt
diabetes. Insulin signals to peripheral tissues to take up glucose and to
halt hepatic glucose production and lipolysis. An insulin resistance
state impairs these responses, causing hyperglycemia, leading to
vascular, nerve and renal complications, among others. At this time,
many aspects of the molecular progression of insulin resistance
remain unclear.
Polycomb group (PcG) proteins assemble into multi-subunit complexes
and repress target genes. PRC2 (Polycomb Repressive Complex 2)
initiates repression and PRC1 maintains repression via histone
methyltransferase and ubiquitin E3 ligase activities, respectively [2,3].
Bmi1 is a member of PRC1 and is necessary for full activity of the
complex. The classically studied targets of the Polycomb complexes
are the Ink4a/Arf locus and the Hox gene clusters, which PRC1 and
PRC2 function to repress. Regulation of the Ink4a/Arf locus has been
studied particularly extensively due to the impact of this locus on
cancer progression and stem cell self-renewal. Overexpression of
Bmi1 allows rapid proliferation, eventually leading to immortalization of
mouse embryonic ﬁbroblasts in culture [4]. Bmi1 was initially identiﬁed
as an oncogene that cooperates with c-myc in B cell lymphomagenesis
and was named as such: B cell-speciﬁc Moloney Murine Leukemia
Virus integration site 1 [5,6,10,7]. Bmi1 was later found to be involved
in cell cycle progression and to be necessary for hematopoietic and
neural stem cell renewal, as Bmi1-deﬁcient mice have severe he-
matopoietic and neurological abnormalities [9,11].
The most well-characterized target of Bmi1 is the Ink4a/Arf locus,
which encodes two key regulators of cell cycling, p16 (Ink4a) and p19
(Arf). While some Bmi1 null phenotypes can be fully explained by
regulation of this locus, others cannot. For instance, the loss of self-
renewal capability in Bmi1 /  neural stem cells is completely
rescued by concomitant deletion of Ink4a/Arf [9]. Additionally, the
drastic reduction in proliferation after Bmi1 knockdown is completely
rescued by knockdown of Ink4a in cultured mouse islets [10].I n
contrast, Bmi1 null mice have a 50% reduction in body weight that is
not signiﬁcantly rescued by the genetic loss of either Arf alone or both
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Bmi1 null mice is only partially rescued by co-deletion of Ink4a/Arf
[11]. These observations have contributed to the recognition that Bmi1
(and PRC1) regulates targets beyond Ink4a/Arf, the identity of which
are only beginning to be understood. Complicating the identiﬁcation of
Bmi1 targets is the lack of a clear consensus binding sequence that
deﬁnes the location to which PRC complexes are recruited [12,13].
The severe phenotypes limiting postnatal survival of Bmi1 null mice
have precluded exploration of the role of Bmi1 in regulating glucose
homeostasis in the adult animal. Here, we study the metabolic role of
Bmi1 in adult Bmi1þ/  mice and, surprisingly, ﬁnd enhanced insulin
sensitivity in vivo and enhanced insulin signaling in liver and muscle,
thereby deﬁning a novel metabolic role of Bmi1.
2. MATERIALS AND METHODS
2.1. Animals and physiological experiments
All animal experiments were performed according to procedures
approved by the Institutional Animal Care and Use Committee of the
University of Pennsylvania. Animals were placed on high fat diet (60%
fat), low fat diet (10% fat) (Research Diets Inc., New Brunswick, NJ)
or standard chow (12.7% fat; LabDiet, St. Louis, MO) at weaning.
Bmi1þ/  mice were previously described [8]. Mice were maintained on
a C57BL/6N background. All experiments were performed on males
15e18 weeks of age, except where otherwise noted. For glucose
tolerance tests, 18 week old males were fasted overnight, given 1 g/kg
glucose via intra-peritoneal (IP) injection and blood glucose was
measured by handheld glucometer at 0, 15, 30, 60, and 120 min after
injection. For insulin tolerance tests, animals were fasted 6 h prior to IP
injection of 1.0 or 1.5 U/kg insulin (NovolinR, Novo Nordisk, Princeton,
NJ) and blood glucose was measured byhandheld glucometer at 0, 15,
30, 60, and 120 min after injection. For insulin secretion assays, blood
was collected at time 0 and 3 min after glucose bolus. Insulin
concentration was measured by ELISA (Crystal Chem Inc., Downers
Grove, IL).
Liver-speciﬁc insulin receptor knockout (LIRKO) mice have been
described previously [14]. Physiological measurements were taken
and livers harvested from LIRKO and control littermates at 6 months of
age for further analysis.
2.2. Body composition measurements
Body composition was assessed using a 3-in-1 NMR machine by
EchoMRI (Houston, TX).
2.3. Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic-euglycemic clamp was performed according to
previously published procedures [15e17]. Brieﬂy, [3e3H] glucose
was used to measure baseline glucose kinetics. The hyperinsulinemic
clamp utilized a continuous infusion of 2.5 mU/kg/min insulin
(Humulin; Eli Lilly, Indianapolis, IN) and a variable intravenous infusion
of 20% glucose (w/v) to maintain blood glucose levels at 120e
140 mg/dL. 2-deoxy-D-[1-14C] glucose was used to estimate glucose
uptake.
2.4. Stimulation of insulin signaling pathways
For analysis of Akt phosphorylation, 15-week-old males were injected
IP with saline or 1.125 U/kg insulin. Tissues were harvested
20 min later and snap-frozen for later use. For analysis of other insulin
signaling components, 5 U insulin was injected into the inferior vena
cava of 15-week-old males. Tissues were harvested 2 min later and
snap-frozen for later use.
2.5. Western blot analysis
Livers, gastrocnemius muscles, and isolated hepatocytes were
sonicated in lysis buffer (50 mM TriseC l ,p H7 . 8 ,2 %S D S ,1 0 %
glycerol, 10 mM Na4P2O7, 100 mM NaF, 6 M urea, 10 mM EDTA).
Proteins were resolved by SDS-PAGE and immunoblotted with the
following antisera: rabbit anti-Akt (1:1000, Cell Signaling), rabbit
anti-phospho-Akt (1:1000, Cell Signaling), mouse anti-Ran
(1:10,000, BD Biosciences), mouse anti-Bmi1 (1:1000, Millipore),
rabbit anti-p-ERK1/2 (1:1000, Cell Signaling), rabbit anti-ERK1/2
(1:1000, Cell Signaling), mouse anti-p-STAT5 (1:1000, upstate),
rabbit anti-STAT5 (1:1000, Santa Cruz), rabbit anti-p-IRS1 (1:1000,
Millipore), rabbit anti-IRS1 (1:1000, Santa Cruz), rabbit anti-p-IR/
IGFR (1:1000, Cell Signaling), rabbit anti-IR/IGFR (1:1000, Cell
Signaling), mouse anti-tubulin (1:10,000, Sigma). Blots were quan-
tiﬁed using ImageJ software.
2.6. RNA isolation and quantitative RT-PCR
Total RNA was isolated from snap-frozen liver using Trizol (Invitrogen,
Carlsbad, CA), according to the manufacturer’s instructions.
Ribosome-associated RNA was isolated using the RNeasy mini kit
(Qiagen). DNA was digested using the TURBO DNA-free kit (Life
Technologies). RNA concentrations were measured on a Nanodrop ND-
1000 spectrophotometer (Thermo-Scientiﬁc, Wilmington, DE). RNA
integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). To synthesize cDNA, RNA was reverse-
transcribed with SuperScript III (Invitrogen) according to manufac-
turer’s instructions. Quantitative real time PCR was performed on a
Bio-Rad CFX384 384-well thermal cycler.
2.7. Hepatocyte isolation
Hepatocytes were isolated from 15-week-old male mice following a
5 h fast using Liver Perfusion Media (Invitrogen, Carlsbad, CA) and
Kreb’s Ringer Bicarbonate Buffer (Sigma, St. Louis, MO) supplemented
with Collagenase and DNase (Worthington Biochemical Corporation,
Lakewood, NJ) with a modiﬁed two-step perfusion protocol [18]. He-
patocytes were seeded at a density of 2.5   105 cells per well in
collagen-I-coated 12-well plates M199 media plus 10% FBS plus
penicillin/streptomycin. Cells were allowed to attach w2 h prior to
2 h serum starvation. Cells were then treated with the indicated
concentrations of insulin for 20 min.
2.8. Statistical analysis
All data are represented as mean   SEM. Statistical signiﬁcance was
assessed by two-tailed Student’s t test or two-way ANOVA (Prism
GraphPad).
3. RESULTS
3.1. Bmi1 levels correlate inversely with age and insulin sensitivity
The decline in Bmi1 transcript and protein early in life has been well-
described in the beta cells [19]. However, to date, no studies have
explored Bmi1 levels with age in liver. Livers were harvested from
C57BL/6N mice 2 weeks, 8 weeks, 16 weeks, and 24 weeks of age.
Between 2 weeks and 8 weeks, there was a marked decline in Bmi1
protein, correlating with observations in other tissues (Figure 1A).
Surprisingly, in older animals there was a dramatic increase in protein
levels. Given the well-established decline in insulin sensitivity with age,
we hypothesized that Bmi1 protein is correlated to serum insulin levels
and/or insulin sensitivity.
To determine whether Bmi1 levels correlate inversely with insulin
sensitivity in another model, we examine Bmi1levels in the LIRKO(liver
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display reduced body weight, severe fed hyperglycemia and hyper-
insulinemia, as well as an abolishment of insulin-induced suppression
of hepatic glucose production [14]. Notably, Bmi1 protein levels were
increased in the livers of 6-month-old LIRKO mice, compared to control
littermates (Figure 1B). Consistent with insulin resistance, these LIRKO
animals displayed the expected phenotypes of hyperglycemia,
hyperinsulinemia, and reduced body weight (Figure 1CeE). Thus,
Bmi1 protein levels are inversely correlated with insulin sensitivity in
two well-established models of insulin resistance.
3.2. Bmi1þ/  mice are partially protected from HFD-induced
insulin resistance
To assess the potential role of Bmi1 in insulin sensitivity, we char-
acterized glucose homeostasis of Bmi1-deﬁcient mice. In order to
exacerbate what we predicted might be a mild phenotype, Bmi1þ/ 
males and Bmi1þ/þ littermates were placed on a high fat diet at
weaning and followed through 18 weeks of age. Bmi1 heterozygosity
resulted in an approximate 60% reduction in Bmi1 protein (Figure 2A).
High fat diet induced an equivalent degree of weight gain in both
genotypes (Figure 2D). Surprisingly, glucose tolerance was not worse
in Bmi1þ/  mice, rather there was a trend toward improved
glucose tolerance (Figure 2B; p ¼ 0.12 by two-way ANOVA for HFD-fed
Bmi1þ/þ vs HFD-fed Bmi1þ/ ). Insulin tolerance testing (ITT) revealed
that Bmi1 heterozygosity confers partial protection from high fat diet-
induced insulin resistance (Figure 2C; p ¼ 0.0095 by two-way ANOVA
for HFD-fed Bmi1þ/þ vs HFD-fed Bmi1þ/ ). Bmi1 null animals have
multiple phenotypes resulting from severe deﬁciencies in cell repli-
cation, including stunted growth [8]. In contrast, body weight and
composition were indistinguishable between Bmi1þ/þ and Bmi1þ/ 
littermates (Figure 2DeE). These observations indicate that the role of
Bmi1 in whole-body insulin sensitivity is independent of body weight or
adiposity.
3.3. Bmi1 null mice may be hypersensitive to insulin
Impaired glucose tolerance at an early age due to reduced insulin
secretion has been observed in Bmi1 null animals [10]. This phenotype
was recapitulated in our hands, with marked hyperglycemia evident at
10 weeks of age (Supp. Figure 1A); however, we also observed a trend
toward hyper-responsiveness to insulin on insulin tolerance testing
(Supp. Figure 1B). Due to grossly impaired survival of Bmi1 null mice
beyond weaning, this observation could not be extended. However,
combined with our observations of adult Bmi1þ/  animals, these data
suggest a gene dosage dependent role of Bmi1 in whole animal insulin
sensitivity.
3.4. Bmi1þ/  mice require less circulating insulin to maintain
glucose homeostasis
Similar to HFD-fed Bmi1þ/  mice, Bmi1þ/  mice fed a low fat diet
(LFD) had normal glucose tolerance (Figure 2B). Although insulin
sensitivity was not different between LFD-fed Bmi1þ/  mice and wild
type littermates, we observed lower insulin secretion in response to
a glucose bolus in Bmi1þ/  animals (Figure 2C,F). In contrast to
Bmi1 /  mice, in which decreased insulin secretion due to reduced
beta cell mass is associated with marked impairment of glucose ho-
meostasis, the reduction of insulin in the face of normal glucose
tolerance in LFD-fed Bmi1þ/  mice suggests an appropriate adaptive
response to enhanced insulin sensitivity.
3.5. Hyperinsulinemic-euglycemic clamp reveals increased insulin
sensitivity in low fat diet-fed Bmi1þ/  mice
We hypothesized that a more sensitive measure might reveal an insulin
sensitivity phenotype in these animals. Therefore, we assessed insulin
sensitivity in LFD-fed mice using a hyperinsulinemic-euglycemic
clamp. There was no difference in basal blood glucose or hepatic
glucose production (HGP; Figure 3AeB); however, Bmi1þ/  mice
required a glucose infusion rate (GIR) more than twice that of Bmi1þ/þ
Figure 1: Bmi1 levels correlate positively with age and insulin resistance. (A) Livers harvested from wildtype mice of indicated ages. Western blots of lysates from snap-frozen
tissue showing levels of Bmi1 protein with age. (BeE) 6-month-old LIRKO and control littermates. (B) Western blots of lysates from snap-frozen tissue showing levels of Bmi1
protein. (C) Blood glucose levels, (D) body weight, and (E) circulating insulin levels from LIRKO and control animals. *p < 0.05.
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echoing our previous observations of improved whole-body insulin
sensitivity (Figure 3C). The suppression of HGP by insulin during the
clamp was greatly increased in Bmi1þ/  mice (Figure 3D; 77% sup-
pression vs 40% in controls; p ¼ 6.5   10 5), suggesting that Bmi1
heterozygosity results in greater responsiveness of the liver to insulin
stimulation. During the clamp, the glucose disposal rate (Rd) was 67%
higher in Bmi1þ/  mice (Figure 3E; p ¼ 0.0011), indicating a differ-
ence in responsiveness of peripheral tissues to insulin as well. Glucose
uptake to muscle was elevated 57% (Figure 3F; p ¼ 0.06), while there
Figure 2: Bmi1
þ/  mice are partially protected from high fat diet-induced insulin resistance and require less insulin to maintain glucose homeostasis. (A) Western blots of lysates
from Bmi1
þ/þ and Bmi1
þ/  male liver lysates showing levels of Bmi1 protein. Quantiﬁcation of western blots from 5 animals per genotype. (BeC) Glucose and insulin tolerance
tests of 16e18 week old LFD and HFD-fed Bmi1
þ/þ and Bmi1
þ/  males (B) 1 g/kg IP glucose bolus, p¼ 0.1211 by two-way ANOVA for HFD Bmi1
þ/þ vs HFD Bmi1
þ/  and (C)
1.5 U/kg IP insulin, p ¼ 0.0095 by two-way ANOVA for HFD Bmi1
þ/þ vs HFD Bmi1
þ/ . (D) Body weights of LFD and HFD-fed Bmi1
þ/þ and Bmi1
þ/  males. (E) Lean and fat mass
unaffected in HFD Bmi1
þ/þ and Bmi1
þ/  mice at 29 weeks of age, as measured by NMR. n ¼ 7e8 mice per genotype for all assessments. *p < 0.05 **p < 0.01 vs Bmi1
þ/þ (F)
Plasma insulin at 0 and 3 min after 2 g/kg IP glucose bolus. *p < 0.05; n ¼ 13e15 per genotype.
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Together, these results suggest a role for Bmi1 in modulation of insulin
signaling in liver and possibly muscle. Given the robust phenotype
observed in liver, we ﬁrst examined insulin signaling in that tissue.
3.6. Hepatic insulin signaling is enhanced by Bmi1 heterozygosity
Aftera5hfasttominimizestimulationbyendogenousinsulin,Bmi1þ/þ
andBmi1þ/ micewereinjectedIPwithsalineorinsulin20minpriorto
sacriﬁce. Western blot analysis of liver lysates revealed no effect of
either genotype or insulin treatment on total Akt levels (Figure 4A);
however, Akt phosphorylation levels in heterozygous mice were lower
at baseline as compared to controls, suggesting reduced basal insulin
signaling in Bmi1þ/  livers. This supports the observation from whole
animal physiology that less insulin is needed to maintain normal
glucose homeostasis in the Bmi1 heterozygous animals (Figure 2F).
Upon insulin stimulation, Akt phosphorylation was higher in Bmi1þ/ 
liver lysates, compared to controls, indicating enhanced signal
transduction in response to insulin (Figure 4AeB; 2.2-fold change in
Bmi1þ/þ vs 8.9-fold in Bmi1þ/ ).
To determine whether these ﬁndings reﬂect an alteration of insulin
sensitivity withinhepatocytes, we performedstudies inculturedprimary
hepatocytes isolated from Bmi1þ/þ and Bmi1þ/  mice. Here we
Figure 3: Hyperinsulinemic-euglycemic clamp reveals increased insulin sensitivity in low fat diet-fed Bmi1
þ/  mice. Hyperinsulinemic-euglycemic clamp performed on 30 week-
old males on LFD. Target glucose 120e140 mg/dL n ¼ 5 mice per genotype. (A) Basal blood glucose levels, (B) basal hepatic glucose production, and (C) glucose infusion rate
during clamp. Radioactive tracers were administered and quantitated to calculate (D) hepatic glucose suppression, (E) glucose disposal rate, and glucose uptake to muscle (F) and
adipose tissue (G). *p < 0.005 compared to Bmi1
þ/þ;* * p < 0.001 compared to Bmi1
þ/þ.
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insulin doses. Hepatocytes isolated from Bmi1þ/  animals had detect-
able levels ofAktphosphorylationat lower dosesofinsulin ascompared
to Bmi1þ/þ hepatocytes (Figure 4CeD). Additionally, the maximal
level of Akt phosphorylation was higher in these hepatocytes.
Together, these experiments suggest a hepatocyte-autonomous role for
Bmi1 in modulating sensitivity of insulin signaling, speciﬁcally Akt
phosphorylation.
3.7. Activity of early insulin signaling pathway not altered in
Bmi1þ/  mice
In order to further investigate the effect of Bmi1 heterozygosity on
insulin signaling, critical signaling events upstream of and parallel to
Akt phosphorylation were assessed by immunoblot (Figure 5A). The
ﬁrst step in the insulin signaling pathway, insulin receptor phos-
phorylation, showed a comparable response to insulin in both
groups, although there was a slight increase in basal levels of IR
phosphorylation in Bmi1þ/  animals (Figure 5B). Similarly, there was
no statistically signiﬁcant difference in IRS1 phosphorylation between
genotypes when stimulated by insulin, although a trend toward
reduced IRS1 phosphorylation was observed at baseline in the
Bmi1þ/  animals (p ¼ 0.07) (Figure 5C). As an important pathway
parallel to Akt signaling, ERK1/2 phosphorylation was also
measured. The response to insulin was variable at this time point
and no signiﬁcant difference was observed between genotypes
(Figure 5D).
Given the well-described role of Bmi1 in repressing transcription of
target genes, we sought to determine whether the expression of the
insulin signaling proteins upstream of Akt was altered in Bmi1þ/ 
livers. There were no differences in the levels of the receptors (IR,
Igf1r), adaptor proteins (Irs1, Irs2, p85) or proteins that regulate activity
of the core pathway components (Pten, Ptb1b, Pdk1, Sos1, Pp2a,
Phlpp1, Phlpp2), suggesting that Bmi1 does not regulate expression of
these genes.
Figure 4: Hepatic insulin signaling is enhanced by Bmi1 heterozygosity. (AeB) 15-week-old males fasted 5 h and then injected IP with saline or 1.125 U/kg insulin. Livers
harvested 20 min later and lysates assessed by western blot. (A) Representative Western blots showing levels of phospho-Akt and total Akt. Ran immunoreactivity was used as the
loading control. (B) Quantiﬁcation of phospho- and total Akt levels. The ratio of phospho-Akt/total Akt is shown. n ¼ 4e5 per genotype and treatment. *p < 0.05 vs Bmi1
þ/þ
saline; **p < 0.05 vs Bmi1
þ/þ insulin. (CeD) Cultured hepatocytes isolated from 15-week-old males treated with indicated dose of insulin for 20 min prior to harvest. Lysates
assessed by western blot. (C) Representative Western blots showing levels of phospho-Akt and total Akt. (D) Quantiﬁcation of phospho- and total Akt levels. The ratio of phospho-
Akt/total Akt is shown. Results shown obtained from n ¼ 5 independent hepatocyte isolations per genotype. p < 0.001 by two-way ANOVA. *p < 0.05 vs WT; **p < 0.001 vs WT.
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Given the robust enhancement of Akt signaling in liver (Figure 4), we
hypothesized that a similar enhancement is responsible for the trend
toward increased glucose uptake seen in the muscle of Bmi1þ/ 
animals during the clamp (Figure 3). Lysates of muscle tissue taken
from the same animals as above were analyzed by western immu-
noblot. As expected, Bmi1 protein was reduced in Bmi1þ/  muscle
(Supp. Figure 2A). Similar to liver, Akt phosphorylation increased
higher above baseline in response to insulin stimulation in Bmi1þ/ 
muscle, as compared to Bmi1þ/þ (Supp. Figure 2B; 1.6-fold change in
Bmi1þ/þ vs 3.6-fold in Bmi1þ/ ).
4. DISCUSSION
We identify a novel role for the Polycomb protein, Bmi1, in the
development of insulin resistance. Insulin resistance, caused by age or
Figure 5: Early insulin signaling in liver unaffected by Bmi1 heterozygosity. (AeD) 15 week old males fasted for 5 h and then injected with saline or 5 U insulin into the IVC. Livers
were harvested 2 min later and lysates assessed by western blot. (A) Western blots showing levels of phosphorylated and total IR, IRS1, and ERK1/2. (B) Quantiﬁcation of phospho-
and total IR levels. The ratio of phospho-IR/total IR is shown. (C) Quantiﬁcation of phospho- and total IRS1 levels. The ratio of phospho-IRS1/total IRS1 is shown. (D) Quantiﬁcation of
phospho- and total ERK1/2 levels. The ratio of phospho-ERK1/2/total ERK1/2 is shown. (E) RNA isolated from 15-week-old male livers and assessed by qRT-PCR. n ¼ 5e6 per
genotype and treatment. *p < 0.05; **p < 0.01; ***p < 0.0001.
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Reduced Bmi1results in alterations in insulin signaling in both liver and
muscle tissue, which appear to contribute to a striking improvement in
whole-body insulin sensitivity. It appears that this sensitization is a
result of increased activity of Akt, with more proximal members of the
insulin signaling pathway being unaffected. Homozygous loss of Bmi1
has been associated with severe glucose intolerance and diabetes due
to stunted beta cell replication [10]. It was therefore surprising to
discover the favorable metabolic phenotype of Bmi1þ/  mice. In
addition to a lack of impaired glucose homeostasis, we observed a
trend toward protection from HFD-induced glucose intolerance and a
clear sensitization of insulin responsiveness in these animals. Our data
therefore indicate a role for Bmi1 in extra-islet tissues in regulating
glucose homeostasis.
An age related decline in Bmi1 expression has been observed in other
tissues and is associated with a decline in replication [19]. An initial
reduction of Bmi1 protein levels occurs between 2 and 8 weeks in liver
as well; however, Bmi1 levels subsequently increase dramatically with
progressive age, surpassing the levels seen in juvenile livers by 30
weeks. The mechanisms underlying these temporally dynamic
changes in Bmi1 levels warrant further investigation.
We ﬁnd a striking effect of Bmi1 gene dosage on Akt activity. A
comprehensive analysis of early insulin signaling events revealed no
difference in activation of IR, IRS1, or ERK1/2, nor alterations in the
transcript levels of known regulators of Akt, including IRS1, Akt phos-
phatases,andthePI3Kregulatorysubunitp85.Thus,themechanismby
which Bmi1 inﬂuences Akt activity also warrants further investigation.
We also noted a decrease in plasma insulin in Bmi1þ/  animals
following a glucose bolus. While we interpret this to indicate an
adaptive response to reduced insulin requirement by more sensitive
Bmi1þ/  tissues, our data do not rule out the possibility that the livers
of Bmi1þ/  animals are clearing glucose more rapidly from the blood.
Given the supporting molecular data showing enhancement of insulin
signaling, we believe this to be an unlikely explanation.
The observations that Bmi1 null animals have no discernible difference
in hepatocyte proliferation compared to wildtype [20] and that p16
expression is not detectable in hepatocytes (data not shown) suggest a
non-classical, proliferation-independent role of Bmi1 in the liver.
Although recent studies have begun to explore the potential for Bmi1
action independent of its regulation of the Ink4a/Arf locus, Bmi1targets
identiﬁed in neural stem cells [21] were not dysregulated in Bmi1þ/ 
liver (data not shown), suggesting that Bmi1 targets may be tissue-
speciﬁc. Further, the lack of a clear consensus sequence for
mammalian PRC1 binding [12,13], complicates efforts to predict Bmi1
targets in the liver. A direct determination of Bmi1 targets in liver by
chromatin immunoprecipitation and high throughput sequencing will
be required to identify the direct Bmi1 targets involved in insulin action
in the liver. Further, it is possible that derepression of multiple genes
contributes to this phenotype.
Our current model is limited by the global and heterozygous nature of
the genetic deletion, which complicates interpretation of how speciﬁc
tissues are contributing to the overall improvement in insulin sensi-
tivity. It is likely that tissues in addition to liver contribute to the insulin
sensitivity phenotype. The marked increase in glucose disposal rate
indicates that glucose uptake in peripheral tissues is a key contributor
to this phenotype, which we speculate to be due, at least in part, to
Bmi1 regulation of insulin signaling in muscle. Additionally, it is still
unclear whether the role of Bmi1 in insulin sensitivity is gene dosage
dependent, since the severely shortened lifespan of the Bmi1 null mice
precludes the type of analysis we present here. Future work in a
tissue-speciﬁc model, when one becomes available, will circumvent
these limitations. Complete ablation of Bmi1 in liver may further protect
animals from age- and/or high fat diet-induced insulin resistance,
compared to the heterozygous deletion described here.
Given the myriad of negative phenotypes associated with Bmi1 dele-
tion, it was unanticipated to see such a strikingly positive effect of
Bmi1 heterozygosity. Additionally, further analysis may reveal a new
mechanism for regulation of Akt activity. Our observations highlight the
role of Bmi1 in regulating insulin sensitivity as well as broaden the
roles of Bmi1and PRC1beyond their classical regulation of cell cycling.
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